MedPath

Prospective Descriptive Study of Injuries Associated to Anterior Shoulder Dislocations in Patients Over 40 Years

Recruiting
Conditions
Anterior Glenohumeral Dislocations
Interventions
Procedure: Reduction
Registration Number
NCT05898243
Lead Sponsor
Corporacion Parc Tauli
Brief Summary

The glenohumeral joint has the highest rate of dislocation of the whole body, due to its high mobility and the special characteristics of its anatomy. It is estimated that every year between 1-2% of the population will suffer from glenohumeral dislocation. The vast majority of studies are based on young patients under the age of 40, given that at this age they have the higher incidence and at the same time, they have higher redislocation index. However, the investigators are in front of a more active population with a longer life expectancy. That is why the cases of anterior glenohumeral dislocations are increasing in people older than 40 years. Given that most studies focus on younger patients, the investigators lack knowledge about which injuries are associated with dislocation at this age and whether these influence its clinical evolution.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
120
Inclusion Criteria
  • More than 40 years old
  • First episode of traumatic anterior gelnohumeral dislocation seen in Rx
  • Acceptance to be checked over 2 years
  • Acceptance to be submitted to TAC, NMR, EMG and Bilateral Ultrasound
Exclusion Criteria
  • Previous fractures in this extremity
  • Previous neurovascular lesions in this extremity
  • Other associated lesions
  • Cognitive alterations or dementia which prevent completing the protocols. Patients with <14 points in Mini-mental test.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Humeral anterior dislocationReductionPatients presenting a first episode of humeral anterior dislocation and who are over 40 years old.
Primary Outcome Measures
NameTimeMethod
Characterization of associated lesionsAt the three months visit including assessment of NMR/EMG/TAC/Bilateral Ultrasound
Secondary Outcome Measures
NameTimeMethod
Type of treatment3, 6, 12 and 24 months
Constant Functional Test3, 6, 12 and 24 months
WOSI test3, 6, 12 and 24 months
SST3, 6, 12 and 24 months
Redislocations3, 6, 12 and 24 months

Trial Locations

Locations (1)

Hospital Parc Taulí

🇪🇸

Sabadell, Barcelona, Spain

© Copyright 2025. All Rights Reserved by MedPath